CAMBRIDGE, Mass. (January 3, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today congratulates Robert S. Langer, ScD, InVivo co-founder and member of the Company’s scientific advisory board, on receiving the National Medal of Technology and Innovation. President Barack Obama will present the award to Dr. Langer, who also won the National Medal of Science in 2006, at a White House ceremony in early 2013.
Dr. Langer, the David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT), is among 23 renowned researchers who have been awarded the nation’s highest honors for scientists, engineers, and inventors this year. With this award, he joins the ranks of five engineers and inventors from MIT who have earned the same honor, and becomes one of three Americans to have won both the National Medal of Science and the National Medal of Technology and Innovation.
“The impact of Bob’s biomaterials research and drug/cell delivery innovations are enormous, and his discoveries have now led to over 55 products either currently in clinical trials or already approved by the FDA,” said InVivo Chief Executive Officer Frank Reynolds. “The range of Bob’s humanitarian impact is only exceeded by his dedication to help people with ‘tough to solve’ unmet medical needs. InVivo is fortunate to benefit from many of his patents and as we look forward to beginning clinical studies in early 2013, our team couldn’t be happier to see Bob recognized by President Obama for his major contributions to the worlds of biomaterials, tissue engineering, tissue regeneration and drug delivery.”
For more on the National Medical of Technology and Innovation please visit http://www.whitehouse.gov/the-press-office/2012/12/21/president-obama-honors-nation-s-top-scientists-and-innovators.
About the Neuro-Spinal Scaffold
Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and acts as a physical substrate for nerve sprouting. Appositional healing to spare spinal cord tissue, decreased post-traumatic cyst formation, and decreased spinal cord tissue pressure have been demonstrated in preclinical models of spinal cord contusion injury. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device designation and is currently being studied in a pilot study for the treatment of complete (AIS A) traumatic acute spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a pioneering biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011 the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect” and similar expressions, and include statements regarding the enrollment of additional patients in the scaffold pilot study following the reopening of enrollment and its ability to conduct a second pivotal study. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the Company’s ability to obtain FDA approval to commercialize its products; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, as amended, and its other filings with the SEC, including the Company’s Form 10-Qs and current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.